Axicabtagen-Ciloleucel (3, reassessment) (Yescarta®) – Diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma, after at least 2 prior therapies
|Pharm. company||Gilead Sciences GmbH|
|G-BA procedure ID||2022-05-15-D-820|
|ICD-10 codes||C83.3Diffuse large B-cell lymphoma, C85.1Unspecified B-cell lymphoma|
|Therapeutic area||Oncological diseases ORPHAN|
|Reason for procedure||
Reassessment: G-BA limitation
Original resolution: Axicabtagen-Ciloleucel (02.05.2019)
|Regulatory status||ATMP (CAR-T)|
|G-BA resolution "Anwendungsgebiet des Beschlusses" (German)|
Yescarta is used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) after two or more systemic therapies.
|a)||Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more systemic therapies||– (Orphan drug)|
|b)||Adults with relapsed or refractory primary mediastinal large B cell lymphoma (PMBCL) after two or more systemic therapies.||– (Orphan drug)|
9. Associated procedures
<< List of all resolutions
The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.